Profile
Sector:
HealthcareIndustry:
Diagnostics & ResearchCountry:
United StatesIPO:
17 July 2014Website:
http://caredx.comNext earnings report:
28 February 2025Last dividends:
N/ANext dividends:
N/APrice
after hours | Tue, 19 Nov 2024 21:20:00 GMTDividend
Analysts recommendations
Institutional Ownership
CDNA Latest News
The heavy selling pressure might have exhausted for CareDx (CDNA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
CareDx, Inc (NASDAQ:CDNA ) Q3 2024 Earnings Conference Call November 4, 2024 4:30 PM ET Company Participants Greg Chodaczek - Managing Director John Hanna - President and Chief Executive Officer Abhishek Jain - Chief Financial Officer Conference Call Participants Bill Bonello - Craig-Hallum Mark Massaro - BTIG Brandon Couillard - Wells Fargo Yi Chen - H.C. Wainwright Mason Carrico - Stephens Inc Thomas DeBourcy - Nephron Research Operator Good day, everyone, and welcome to today's CareDx, Inc. Third Quarter 2024 Earnings Conference Call.
NEW ORLEANS, LA / ACCESSWIRE / October 25, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
NEW ORLEANS , Oct. 11, 2024 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on October 8, 2024, CareDx granted to Jing Huang, the Company's newly appointed Chief Data and AI Officer, 15,547 restricted stock units (“RSUs”) and an option to purchase 22,248 shares.
NEW ORLEANS, LA / ACCESSWIRE / September 30, 2024 / Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq.
CDNA has resolved corporate instability and insurance issues, showing potential for sustainable growth with innovative transplant testing services like AlloSure, AlloMap, and HeartCare. CDNA's products are supported by scientific literature and recent Medicare coverage expansions, enhancing their market potential and revenue growth prospects. The appointment of CEO John W. Hanna provides stable leadership and strategic direction for long-term objectives.
Morris Kandinov Investigating CareDx, Inc., Puerto Rico Residents Tax-Free Fund, Inc., Puerto Rico Residents Tax-Free Fund VI, Inc., and Tax Free Fund.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA)- The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, on September 12, 2024, CareDx granted an option to purchase 100,651 shares of CareDx's common stock (the “Kennedy Inducement Option”) and 70,101 restricted stock units (the “Kennedy Indu.
BRISBANE, Calif.--(BUSINESS WIRE)--CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ — a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers — today announced that, as an inducement material to entering into employment with CareDx, on September 12, 2024, 14 new employees were awarded restricted stock units (RSUs) for an aggregate of 44,000 shares o.
- 1(current)
What type of business is CareDx?
CareDx, Inc. is a leading precision medicine company focused on discovering, developing, and commercializing clinically differentiated, high-value medical solutions for transplant patients and caregivers. CareDx, Inc. was founded in 1998 and is headquartered in South San Francisco, California. The company also develops, manufactures, and markets products that increase the likelihood of successful transplantation by facilitating matching between donor and recipient stem cells and organs. Key products of CareDx, Inc. include: - AlloSure Kidney - a cell-free DNA obtained from the donor (dd-cfDNA) solution for kidney transplant patients - AlloMap Heart - a gene expression solution for patients who have undergone heart transplantation.
What sector is CareDx in?
CareDx is in the Healthcare sector
What industry is CareDx in?
CareDx is in the Diagnostics & Research industry
What country is CareDx from?
CareDx is headquartered in United States
When did CareDx go public?
CareDx initial public offering (IPO) was on 17 July 2014
What is CareDx website?
https://caredx.com
Is CareDx in the S&P 500?
No, CareDx is not included in the S&P 500 index
Is CareDx in the NASDAQ 100?
No, CareDx is not included in the NASDAQ 100 index
Is CareDx in the Dow Jones?
No, CareDx is not included in the Dow Jones index
When was CareDx the previous earnings report?
No data
When does CareDx earnings report?
The next expected earnings date for CareDx is 28 February 2025